Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

Chronic obstructive pulmonary disease (COPD) has become a global epidemic and is the
third leading cause of death worldwide. COPD is characterized by chronic airway …

Rationale: Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy
recommends the combination of two long-acting bronchodilators of different pharmacologic …

Cytokines are key players in the initiation and propagation of inflammation in chronic
inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD) …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

Decreasing the frequency and severity of exacerbations is one of the main goals of
treatment for patients with chronic obstructive pulmonary disease. Several studies have …

Inhaled medicines continue to be an essential part of treatment for respiratory diseases such
as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. In addition, inhalation …

Chronic obstructive pulmonary disease (COPD) is significant cause of morbidity and
mortality worldwide. There is mounting evidence suggesting that COPD patients are at …

Objective The present study aimed to evaluate HRQOL and to explore the factors associated
with poor HRQOL among patients with COPD. Methods In the present cross-sectional study …

Chronic obstructive pulmonary disease (COPD) is one of the main health problems
worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive …